Molecular Partners
Develops designed ankyrin repeat protein platform therapies used in ophthalmology, oncology, inflammation, and other therapeutic treatments. Learn more
Launch date
Employees
Market cap
$178m
Enterprise valuation
($5m) (Public information from Sep 2024)
Share price
$4.67 MOLN
Company register number CH-020.3.028.228-2
Zurich Canton of Zürich (HQ)
Authorizing premium user...